{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T07:32:32Z","timestamp":1793431952742,"version":"4.5.0"},"reference-count":15,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2024,2,1]]},"abstract":"<jats:sec id=\"ab-ebr230010-4\"><jats:title>Importance<\/jats:title><jats:p>Epidermal growth factor receptor inhibitors (EGFRis) have been reported to be associated with cutaneous and ocular side effects; however, there is limited evidence of an association between EGFRi treatment and keratitis.<\/jats:p><\/jats:sec><jats:sec id=\"ab-ebr230010-5\"><jats:title>Objective<\/jats:title><jats:p>To determine the association between EGFRi treatment and agents and the risk of new-onset keratitis among patients with lung cancer.<\/jats:p><\/jats:sec><jats:sec id=\"ab-ebr230010-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This US population\u2013based cohort study examined TriNetX data of patients with lung cancer treated with or without EGFRis between May 1, 2003, and October 30, 2023.<\/jats:p><\/jats:sec><jats:sec id=\"ab-ebr230010-7\"><jats:title>Exposures<\/jats:title><jats:p>Treatment with EGFRis, including the first-generation agents gefitinib and erlotinib, the second-generation agent afatinib, and the third-generation agent osimertinib.<\/jats:p><\/jats:sec><jats:sec id=\"ab-ebr230010-8\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>The risk of new-onset keratitis among patients with lung cancer receiving EGFRi treatment was determined using logistic and Cox proportional hazards regression.<\/jats:p><\/jats:sec><jats:sec id=\"ab-ebr230010-9\"><jats:title>Results<\/jats:title><jats:p>Among 1\u202f388\u202f108 patients with lung cancer, 22\u202f225 received EGFRis (mean [SD] age, 69.7 [10.6] years; 62.8% females and 37.2% males). Patients treated with EGFRis had a higher risk of keratitis than nonexposed patients (hazard ratio [HR],\u20091.520; 95% CI, 1.339-1.725). Subtypes of EGFRi-associated keratitis included keratoconjunctivitis (HR, 1.367; 95% CI, 1.158-1.615), superficial keratitis (HR, 1.635; 95% CI, 1.306-2.047), and corneal ulcer (HR, 2.132; 95% CI, 1.515-3.002). Patients taking afatinib had a higher risk of keratitis (HR, 2.229; 95% CI, 1.480-3.356).<\/jats:p><\/jats:sec><jats:sec id=\"ab-ebr230010-10\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>These findings suggest that patients with lung cancer treated with EGFRis may have an increased risk of new-onset keratitis, especially with the second-generation EGFRi afatinib, supporting the need for prompt diagnosis and management of EGFRi-associated ocular issues to prevent serious complications or treatment disruptions.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaophthalmol.2023.6089","type":"journal-article","created":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T16:00:59Z","timestamp":1704988859000},"page":"140","source":"Crossref","is-referenced-by-count":15,"title":["Epidermal Growth Factor Receptor Inhibitors for Lung Cancer and the Risk of Keratitis"],"prefix":"10.1001","volume":"142","author":[{"given":"Pin-Chia","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Chieh","family":"Lin","sequence":"additional","affiliation":[{"name":"Center for Global Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Dana","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin Sheng-Kai","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts"},{"name":"Center for Global Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia"},{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"},{"name":"Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"8","key":"ebr230010r1","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/s41571-022-00639-9","article-title":"Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management.","volume":"19","author":"Cooper","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"14","key":"ebr230010r2","doi-asserted-by":"publisher","first-page":"7022","DOI":"10.1200\/jco.2004.22.90140.7022","article-title":"A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial.","volume":"22","author":"Shepherd","year":"2004","journal-title":"J Clin Oncol"},{"key":"ebr230010r3","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.2147\/DDDT","article-title":"Three generations of epidermal growth factor receptor tyrosine kinase inhibitors developed to revolutionize the therapy of lung cancer.","volume":"10","author":"Zhang","year":"2016","journal-title":"Drug Des Dev Ther"},{"issue":"3","key":"ebr230010r4","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1001\/jamadermatol.2015.4448","article-title":"Comparison of skin toxic effects associated with gefitinib, erlotinib, or afatinib treatment for non-small cell lung cancer.","volume":"152","author":"Chen","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"3","key":"ebr230010r5","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1097\/JTO.0b013e3181645477","article-title":"EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer.","volume":"3","author":"Fong","year":"2008","journal-title":"J Thorac Oncol"},{"key":"ebr230010r6","doi-asserted-by":"publisher","DOI":"10.3389\/ftox.2023.1137637","article-title":"Ocular surface complications following biological therapy for cancer.","volume":"5","author":"Ma","year":"2023","journal-title":"Front Toxicol"},{"issue":"3","key":"ebr230010r7","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.ejca.2013.10.016","article-title":"Ocular adverse events of molecularly targeted agents approved in solid tumours: a systematic review.","volume":"50","author":"Huillard","year":"2014","journal-title":"Eur J Cancer"},{"issue":"1","key":"ebr230010r8","doi-asserted-by":"publisher","first-page":"8079","DOI":"10.1038\/s41598-019-42969-2","article-title":"Epidermal growth factor stimulates transforming growth factor-beta receptor type II expression in corneal epithelial cells.","volume":"9","author":"Shu","year":"2019","journal-title":"Sci Rep"},{"key":"ebr230010r9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ajoc.2016.06.003","article-title":"Erlotinib-associated severe bilateral recalcitrant keratouveitis after corneal EDTA chelation.","volume":"4","author":"Zhou","year":"2016","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"3","key":"ebr230010r10","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1097\/ICO.0000000000001808","article-title":"Bilateral ulcerative keratitis associated with afatinib treatment for non-small-cell lung carcinoma.","volume":"38","author":"McKelvie","year":"2019","journal-title":"Cornea"},{"key":"ebr230010r11","article-title":"Osimertinib-induced keratitis and secondary toxic epidermal necrotic drug eruption\u2014a case report and literature review.","author":"Xu","year":"2023","journal-title":"Curr Drug Saf"},{"issue":"3","key":"ebr230010r12","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s11523-022-00878-x","article-title":"The difference in clinical outcomes between osimertinib and afatinib for first-line treatment in patients with advanced and recurrent EGFR-mutant non-small cell lung cancer in Taiwan.","volume":"17","author":"Huang","year":"2022","journal-title":"Target Oncol"},{"issue":"2","key":"ebr230010r13","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s40264-018-0772-x","article-title":"Safety and tolerability of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in oncology.","volume":"42","author":"Shah","year":"2019","journal-title":"Drug Saf"},{"issue":"2","key":"ebr230010r14","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer.","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"ebr230010r15","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1007\/s00520-012-1645-y","article-title":"Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review.","volume":"21","author":"Borkar","year":"2013","journal-title":"Support Care Cancer"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2813588\/jamaophthalmology_huang_2024_br_230010_1707339378.78126.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T16:01:45Z","timestamp":1708012905000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2813588"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2023.6089","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,1]]}}}